Mercury Biopharmaceutical Selling, General & Admin

Mercury Biopharmaceutical selling, general & admin — quarterly history, peer benchmarks, and growth trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly SG&A Expenses

$4.83M

↓ 59.9% YoY

As of Jun 30, 2026

Annual SG&A Expenses (TTM)

$38.39M

↓ 21.4% YoY

Trailing 12 months ending Jun 30, 2026

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin

Mercury Biopharmaceutical (6932.TWO) FAQ

Stockcircle tracks selling, general & admin for Mercury Biopharmaceutical (6932.TWO), including historical charts and peer comparisons when data is available. Check back as new filings are published, or open the stock overview for a broader fundamental snapshot.

This Selling, General & Admin page is built for Mercury Biopharmaceutical's historical SG&A expenses trend and peer context. When enough reporting periods are on file, the charts below visualize how the metric has moved over time.

Use SG&A expenses as one input alongside growth, profitability, valuation, and ownership activity. Stockcircle links related metric pages and the main 6932.TWO overview so you can move from this figure to the surrounding analysis quickly.